 Home > Medical News > Latest Medical News > GlaxoSmithKline's PD-1 inhibitor Jemperli is approved by the UK

GlaxoSmithKline's PD-1 inhibitor Jemperli is approved by the UK

 Last Update: 2021-06-17
 Source: Internet
 Author: User

Tags

hsv type 2

10 3 soow

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compile | newborn

Recently, the GlaxoSmithKline PD-1 inhibitor Jemperli (dostarlimab) received conditional approval from the Medicines and Healthcare Products Administration (MHRA) for the treatment of recurrent or advanced endometrial cancer
.

Jemperli is a PD-1 blocking antibody, specifically suitable for: recurrence of disease progression, mismatch repair defect (dMMR)/high degree of microsatellite instability (MSI-H) during or after treatment with platinum-containing chemotherapy Patients with sexual or advanced endometrial cancer

This approval is based on the positive results of the open-label, single-group, multi-cohort Phase 1/2 GARNET study (NCT02715284)
.

In this study, the A1 cohort enrolled patients with dMMR/MSI-H recurrence or advanced endometrial cancer who had progressed during or after treatment with platinum-containing chemotherapy

Dr.
Rebecca Kristeleit, oncology consultant for the Gay and St.
Thomas NHS Foundation Trust (GSTT) in the United Kingdom, said: "The approval of Jemperli by the British regulatory agency has added an important new option for female patients with difficult-to-treat endometrial cancer
.

dMMR/MSI-H patients with advanced or recurrent endometrial cancer have limited treatment options and poor prognosis

Currently, GlaxoSmithKline is also conducting other registration studies to evaluate Jemperli as a monotherapy and as part of a combination therapy for the treatment of patients with relapsed or primary advanced endometrial cancer and patients with non-mucinous epithelial ovarian cancer
.

Jemperli belongs to the PD-(L)1 inhibitor family, which is a type of tumor immunotherapy, which aims to use the body's own immune system to fight tumors
.

Up to now, more than 10 PD-1(L)1 inhibitors have been approved for marketing, the leader of which is Merck’s Keytruda

But among these drugs, Jemperli is the first PD-(L)1 inhibitor to obtain regulatory approval for the treatment of endometrial cancer
.

At present, Merck and Eisai's Keytruda and Lenvima combination drug program is under review by regulatory agencies

Reference source: GSK's PD-1 inhibitor Jemperli approved in the UK

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.